SNX-2112
Selleck Chemicals
SKU:S2639-5MG
Couldn't load pickup availability

SNX-2112 is an inhibitor of HSP90 used in studies of target-focused biology. In practice, this places the compound in experiments that measure annotated target biology and downstream cellular responses in cancer and protein homeostasis models.
By inhibiting HSP90, SNX-2112 can be used to examine annotated target biology and downstream cellular responses. That positioning is consistent with concentration-response inhibition and target-dependence studies and with follow-up studies that compare concentration-dependent responses across orthogonal assay formats. In cancer and protein homeostasis models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.
Research Applications
- Target-focused assays involving HSP90
- Concentration-response inhibition and target-dependence studies
- Phenotypic profiling in cancer and protein homeostasis models
- Combination studies with orthogonal perturbagens
Overall, SNX-2112 is appropriate when a defined chemical perturbant is needed to connect HSP90 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer and protein homeostasis models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.
- Targets:
- HSP90
- Target Class:
- Other
- Research Area:
- Cancer • Protein Homeostasis
- CAS No.:
- 908112-43-6
- Molecular Weight:
- 464.48
- Formula:
- C₂₃H₂₇F₃N₄O₃
- SMILES:
- CC1(CC2=C(C(=O)C1)C(=NN2C3=CC(=C(C=C3)C(=O)N)NC4CCC(CC4)O)C(F)(F)F)C
- Storage Temperature:
- -20°C
For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.
The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.